• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Illumina, Merck Serono collaborate to expand companion diagnostics for oncology

Illumina, Merck Serono collaborate to expand companion diagnostics for oncology

March 11, 2015
CenterWatch Staff

Illumina, a San Diego-based provider of sequencing and array-based technologies, has formed a collaboration with Merck Serono, the biopharmaceuticals business of Merck, based in Darmstadt, Germany, to develop a universal next-generation sequencing (NGS)-based oncology diagnostic.

In addition to separate collaborations with AstraZeneca, Janssen Biotech and Sanofi, Illumina and Merck Serono will work to create a universal test system for clinical trials of targeted cancer therapies, with the goal of a more comprehensive tool for precision medicine.

Illumina is working with Merck Serono to develop assays that detect and measure multiple variants simultaneously to support clinical trials. The collaboration toward the universal cancer test will include test development, worldwide regulatory approvals and global commercialization. In parallel, Illumina continues to collaborate with the Actionable Genome Consortium to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm.

“Our collaboration with Illumina around next-generation sequencing will enable us to perform genome studies at a pace unheard of a few years ago, and could lead to the development of several diagnostics,” said Susan Herbert, head of Global Business Development at Merck Serono.

“This agreement is another step forward in realizing the promise of precision medicine,” said Richard Klausner, M.D., Illumina’s chief medical officer. “The U.S. government’s Precision Medicine Initiative, recently announced by President Obama, specifically outlines the need to expand genetically-based clinical trials as a key approach for developing better treatments for cancer.”

Upcoming Events

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

  • VaccinewithNeedle-360x240.png

    2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

  • Dominate-360x240.png

    COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing